ストックスクリーナーアプリを入手
1.555
1.63%
0.025
前日終値:
$1.53
開ける：
$1.57
24時間の取引高:
2.19M
Relative Volume:
15.48
時価総額：
$117.27M
収益：
-
当期純損益:
$-19.57M
株価収益率:
-0.4968
EPS:
-3.13
ネットキャッシュフロー:
$-17.24M
1週間 パフォーマンス:
+1.63%
1か月 パフォーマンス:
-1.58%
6か月 パフォーマンス:
-21.07%
1年 パフォーマンス:
-22.64%
1日の値動き範囲:
$1.52
$1.66
1週間の範囲:
$1.50
$1.66
52週間の値動き範囲:
$1.33
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
名前
Inhibikase Therapeutics Inc
セクター
電話
(302) 295-3800
住所
1000 N. WEST STREET, SUITE 1200, WILMINGTON
IKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.56 | 115.02M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.06 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.89 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.57 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.65 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.09 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Inhibikase Shares Climb After Revised Drug Timeline, Public Offering - MarketScreener
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Inhibikase Therapeutics Prices $100 Million Public Offering - MarketScreener
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus
Is Inhibikase Therapeutics Inc. stock a buy before product launchesJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement - parameter.io
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants - MSN
IKT Announces Pricing Below Previous Closing Price in Latest Off - GuruFocus
Is Inhibikase Therapeutics Inc. reversing from oversold territoryTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Inhibikase Therapeutics prices $100 million public offering - Investing.com
Inhibikase Therapeutics prices $100 million public offering By Investing.com - Investing.com Australia
Inhibikase Therapeutics prices public offering of 46 million shares at $1.45 per share - MarketScreener
Inhibikase Therapeutics (NASDAQ: IKT) prices $100M stock, warrants offering at $1.45 - Stock Titan
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
IKT Announces New Offering Managed by Leading Financial Firms - GuruFocus
Inhibikase Therapeutics (IKT) Launches Public Offering of Common Stock - GuruFocus
Inhibikase Therapeutics announces proposed public offering of common stock and pre-funded warrants - MarketScreener
Inhibikase Therapeutics (IKT) Launches Public Stock Offering - GuruFocus
Inhibikase Therapeutics (IKT) Plans Global Phase 3 Trial for PAH Treatment - GuruFocus
Inhibikase Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Nigeria
Inhibikase Therapeutics stock falls after announcing public offering - Investing.com
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study - TipRanks
Inhibikase Therapeutics to Initiate Pivotal Phase 3 Study for IKT-001 in Pulmonary Arterial Hypertension, Potentially Accelerating FDA Approval Timeline - Quiver Quantitative
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Inhibikase (NASDAQ: IKT) starts stock, pre-funded warrant offering with 30-day 15% option - Stock Titan
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewswire
Inhibikase Therapeutics (Nasdaq: IKT) Plans Single Pivotal Phase 3 PAH Trial of IKT-001 - Stock Titan
Signal strength of Inhibikase Therapeutics Inc. stock in tech scanners - newser.com
Using data models to predict Inhibikase Therapeutics Inc. stock movementRecession Risk & Scalable Portfolio Growth Ideas - newser.com
Top chart patterns to watch in Inhibikase Therapeutics Inc.Recession Risk & Low Risk Entry Point Tips - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiples2025 Market Outlook & Smart Money Movement Tracker - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
How to build a dashboard for Inhibikase Therapeutics Inc. stock2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Can volume confirm reversal in Inhibikase Therapeutics Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Is Inhibikase Therapeutics Inc. stock cheap compared to fundamentalsPortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Will Inhibikase Therapeutics Inc. stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Understanding Inhibikase Therapeutics Inc.’s price movementInflation Watch & Fast Entry Momentum Alerts - newser.com
Key resistance and support levels for Inhibikase Therapeutics Inc. - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock trades below fair value2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com
Key Support and Resistance Levels for Dolfin Rubbers Limited in YEARTrading Volume Surges & Outstanding Growth Opportunities - earlytimes.in
Can Inhibikase Therapeutics Inc. stock maintain operating marginsMarket Sentiment Review & Entry Point Confirmation Signals - newser.com
Will Inhibikase Therapeutics Inc. price bounce be sustainableQuarterly Profit Review & Technical Pattern Recognition Alerts - newser.com
Inhibikase Therapeutics Inc (IKT) 財務データ
収益
当期純利益
現金流量
EPS
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):